Marie Wensien

Marie Wensien

Auto-generated profile, based on publicly available information

Marie Wensien

Department of Molecular Enzymology, Göttingen Center of Molecular Biosciences, Georg-August University Göttingen

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MWMarie Wensien
Marie Wensien
FPFabian Rabe von Pappenheim
Fabian Rabe von Pappenheim
LFLisa-Marie Funk
Lisa-Marie Funk
PKPatrick Kloskowski
Patrick Kloskowski
UCUte Curth
Ute Curth
KTKai Tittmann
Kai Tittmann

19 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
LFLisa-Marie Funk
Lisa-Marie Funk
GPGereon Poschmann
Gereon Poschmann
ACAshwin Chari
Ashwin Chari
FPFabian Rabe von Pappenheim
Fabian Rabe von Pappenheim
KSKim-Maren Stegmann
Kim-Maren Stegmann
KTKai Tittmann
Kai Tittmann
A bstract: Besides vaccines, the development of antiviral drugs targeting SARS-CoV-2 is critical for stopping the current COVID-19 pandemic and preventing future outbreaks. The SARS-CoV-2 main protease (M pro ), a cysteine protease with essential functions in viral replication, has been validated as an effective drug target. Here, we show that M pro is subject to redox regulation and reversibly switches between the enzymatically active dimer and the functionally dormant monomer through redox modifications of cysteine residues. These include sulfenylation, disulfide formation between the catalytic cysteine and a proximal cysteine, and generation of an allosteric lysine-cysteine SONOS bridge that is required for structural stability under oxidative stress conditions, such as those exerted by the innate immune system. We identify homo- and heterobifunctional reagents that mimic the redox switching and possess antiviral activity. The discovered redox switches are conserved in main proteases from other coronaviruses, e.g. MERS and SARS-CoV, indicating their potential as common druggable sites.